These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20516271)

  • 1. Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children?
    Bouazza N; Hirt D; Bardin C; Diagbouga S; Nacro B; Hien H; Zoure E; Rouet F; Ouiminga A; Blanche S; Van De Perre P; Tréluyer JM; Msellati P; Urien S
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3280-6. PubMed ID: 20516271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children?
    Hirt D; Urien S; Olivier M; Peyrière H; Nacro B; Diagbouga S; Zoure E; Rouet F; Hien H; Msellati P; Van De Perre P; Tréluyer JM
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4407-13. PubMed ID: 19635964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years.
    Luo M; Chapel S; Sevinsky H; Savant I; Cirincione B; Bertz R; Roy A
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3676-86. PubMed ID: 27067333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Didanosine population pharmacokinetics in West African human immunodeficiency virus-infected children administered once-daily tablets in relation to efficacy after one year of treatment.
    Hirt D; Bardin C; Diagbouga S; Nacro B; Hien H; Zoure E; Rouet F; Ouiminga A; Urien S; Foulongne V; Van De Perre P; Tréluyer JM; Msellati P
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4399-406. PubMed ID: 19581461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel pharmacokinetic approach to predict virologic failure in HIV-1-infected paediatric patients.
    Bouazza N; Tréluyer JM; Msellati P; Van de Perre P; Diagbouga S; Nacro B; Hien H; Zoure E; Rouet F; Ouiminga A; Blanche S; Hirt D; Urien S
    AIDS; 2013 Mar; 27(5):761-8. PubMed ID: 23719348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 24-Month adherence, tolerance and efficacy of once-a-day antiretroviral therapy with didanosine, lamivudine, and efavirenz in African HIV-1 infected children: ANRS 12103/12167.
    Hien H; Meda N; Diagbouga S; Zoure E; Yaméogo S; Tamboura H; Somé J; Ouiminga A; Rouet F; Drabo A; Hien A; Nicolas J; Chappuy H; Van de Perre P; Msellati P; Nacro B
    Afr Health Sci; 2013 Jun; 13(2):287-94. PubMed ID: 24235926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.
    Musiime V; Kendall L; Bakeera-Kitaka S; Snowden WB; Odongo F; Thomason M; Musoke P; Adkison K; Burger D; Mugyenyi P; Kekitiinwa A; Gibb DM; Walker AS;
    Antivir Ther; 2010; 15(8):1115-24. PubMed ID: 21149918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months.
    Paediatric European Network for Treatment of AIDS (PENTA)
    Antivir Ther; 2010; 15(3):297-305. PubMed ID: 20516550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.
    Dickinson L; Amin J; Else L; Boffito M; Egan D; Owen A; Khoo S; Back D; Orrell C; Clarke A; Losso M; Phanuphak P; Carey D; Cooper DA; Emery S; Puls R;
    Clin Pharmacol Ther; 2015 Oct; 98(4):406-16. PubMed ID: 26044067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term virological efficacy, immune reconstitution, tolerance, and adherence of once-daily dosing of didanosine, lamivudine, and efavirenz in HIV-1-infected African children: ANRS 12103 Burkiname.
    Barro M; Some J; Foulongne V; Diasso Y; Zouré E; Hien H; François R; Michel S; Drabo A; Tamboura H; Ouiminga A; Diagbouga S; Hien A; Yaméogo S; Van De Perre P; Nacro B; Msellati P
    J Acquir Immune Defic Syndr; 2011 Jul; 57 Suppl 1():S44-9. PubMed ID: 21857286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.
    Crespo M; Ribera E; Suárez-Lozano I; Domingo P; Pedrol E; López-Aldeguer J; Muñoz A; Viladés C; Sánchez T; Viciana P; Teira R; García-Alcalde ML; Vergara A; Lozano F; Galindo MJ; Cosin J; Roca B; Terrón A; Geijo P; Vidal F; Garrido M;
    J Antimicrob Chemother; 2009 Jan; 63(1):189-96. PubMed ID: 18988678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of didanosine and lamivudine both once daily plus indinavir in human immunodeficiency virus-infected patients.
    de Mendoza C; Soriano V; Pérez-Olmeda M; Rodríguez-Rosado R; González-Lahoz J
    J Hum Virol; 2000; 3(6):335-40. PubMed ID: 11100914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women.
    Benaboud S; Tréluyer JM; Urien S; Blanche S; Bouazza N; Chappuy H; Rey E; Pannier E; Firtion G; Launay O; Hirt D
    Antimicrob Agents Chemother; 2012 Feb; 56(2):776-82. PubMed ID: 22106227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients.
    Bouazza N; Cressey TR; Foissac F; Bienczak A; Denti P; McIlleron H; Burger D; Penazzato M; Lallemant M; Capparelli EV; Treluyer JM; Urien S
    J Antimicrob Chemother; 2017 Feb; 72(2):490-495. PubMed ID: 27798221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
    Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis.
    Janssen EJH; Bastiaans DET; Välitalo PAJ; van Rossum AMC; Jacqz-Aigrain E; Lyall H; Knibbe CAJ; Burger DM
    Br J Clin Pharmacol; 2017 Jun; 83(6):1287-1297. PubMed ID: 28079918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients.
    Skowron G; Kuritzkes DR; Thompson MA; Squires KE; Goodwin SD; Dusak BA; Tolson JM; Stevens M; Yuen GJ; Rooney JF;
    J Infect Dis; 2002 Oct; 186(7):1028-33. PubMed ID: 12232846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV Infection: the ELADI study.
    Sánchez-Conde M; Palacios R; Sanz J; Rodríguez-Novoa S; Rivas P; Santos J; Sola J; Asensi V; de Mendoza C; Estrada V; Barreiro P; González-Lahoz J; Jiménez-Nacher I; Soriano V
    AIDS Res Hum Retroviruses; 2007 Oct; 23(10):1237-41. PubMed ID: 17961110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
    Berenguer J; González J; Ribera E; Domingo P; Santos J; Miralles P; Angels Ribas M; Asensi V; Gimeno JL; Pérez-Molina JA; Terrón JA; Santamaría JM; Pedrol E;
    Clin Infect Dis; 2008 Oct; 47(8):1083-92. PubMed ID: 18781872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depressive symptoms and exposure to efavirenz in West African HIV-infected adults.
    Marcellin F; Moh R; Carrieri MP; Danel C; Protopopescu C; Gabillard D; Spire B; Anglaret X
    HIV Clin Trials; 2008; 9(6):445-7. PubMed ID: 19203911
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.